Page 1 of Clinical Trials for FOLFIRI, 180 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Recruiting
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in K-RAS/BRAF Mutant Metastatic Colorectal Cancer
Last Updated: April 20, 2012
Condition(s): Colorectal Cancer Metastatic
2
Recruiting
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Last Updated: May 21, 2012
Condition(s): Colorectal Cancer
3
Completed
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Last Updated: April 4, 2012
Condition(s): Colorectal Cancer
4
Active, not recruiting
MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)
Last Updated: January 5, 2012
Condition(s): Metastatic Colorectal Cancer
5
Active, not recruiting
Phase 2 Safety & Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 vs FOLFIRI in KRAS-mutant Metastatic Colorectal Carcinoma
Last Updated: September 29, 2011
Condition(s): Metastatic Colorectal Cancer
6
Active, not recruiting
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
Last Updated: November 15, 2011
Condition(s): Metastatic Colorectal Cancer
7
Completed
A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
Last Updated: April 27, 2011
Condition(s): Colorectal Cancer
8
Active, not recruiting
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Last Updated: September 6, 2011
Condition(s): Colorectal Cancer; Neoplasms, Colorectal
9
Recruiting
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Last Updated: March 28, 2012
Condition(s): Colorectal Cancer
10
Completed
Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients
Last Updated: September 14, 2011
Condition(s): Colorectal Cancer
11
Recruiting
Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI
Last Updated: May 24, 2012
Condition(s): Advanced Adenocarcinoma of the Colon or Rectum
12
Active, not recruiting
Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
Last Updated: March 14, 2012
Condition(s): Colorectal Neoplasms; Neoplasm Metastasis
13
Recruiting
Phase I Trial of Combination of FOLFIRI and SOM 230
Last Updated: February 23, 2012
Condition(s): Gastrointestinal Tumor
14
Active, not recruiting
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
Last Updated: July 21, 2011
Condition(s): Cancer; Carcinoma; Colon Cancer; Colorectal Cancer; Gastrointestinal Cancer; Metastases; Metastatic Cancer; Metastatic Colorectal Cancer; Oncology; Rectal Cancer
15
Recruiting
Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases
Last Updated: February 6, 2012
Condition(s): Colorectal Cancer
16
Completed
Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer
Last Updated: April 30, 2012
Condition(s): Metastatic Colorectal Cancer
17
Completed
Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
Last Updated: January 4, 2010
Condition(s): Colorectal Neoplasms
18
Completed
FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer
Last Updated: October 11, 2010
Condition(s): Metastatic Colorectal Cancer
19
Completed
Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer
Last Updated: January 10, 2012
Condition(s): Gastric Cancer; Metastases
20
Recruiting
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
Last Updated: February 29, 2012
Condition(s): Colorectal Cancer

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=FOLFIRI

Page 1 of Clinical Trials for FOLFIRI, 180 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About